Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01837303 · ClinicalTrials.gov registry record
chemQbiosciences:Manual Liquid Based Cytology
A clinical trial of Cervical Cancer and Cervical Dysplasia, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 76
- Enrollment target
- 1
- Study location
NCT01837303 is a study of Cervical Cancer and Cervical Dysplasia that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 76 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01837303, a study of Cervical Cancer and Cervical Dysplasia, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
Purpose: To assess equivalence between low cost manual liquid based cytology (pap smear) and standard Thin prep cytology screening. Participants: 100-120 healthy women presenting for standard pap smear screening Procedures (methods): After routine care pap smear, another pap smear will be performed and placed in the study medium. Clinical care pap and study pap will be reviewed by a single pathologist to assess for equivalent findings. Hypothesis: Manual liquid based cytology is equivalent to conventional liquid based cytology.
Conditions Studied
Interventions
- PROCEDURE Pap smear
Study Locations (1)
North Carolina
- University of North Carolina Hospitals - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01837303
The ClinicalTrials.gov registry entry for NCT01837303 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (87% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pap smear is the first listed.
NCT01837303 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01837303 about?
NCT01837303 is a clinical study titled "chemQbiosciences:Manual Liquid Based Cytology". Purpose: To assess equivalence between low cost manual liquid based cytology (pap smear) and standard Thin prep cytology screening. Participants: 100-120 healthy women presenting for standard pap smear screening Procedures (methods): After routine care pap smear, another pap smear will be performe...
What is the current status of trial NCT01837303?
This trial is currently completed. The enrollment target is 76 participants. The study started on 2013-05. Estimated completion is 2013-09.
What conditions does trial NCT01837303 study?
This clinical trial studies the following conditions: Cervical Cancer, Cervical Dysplasia.
What interventions are being tested in trial NCT01837303?
The interventions under investigation include: Pap smear (PROCEDURE).
Who is sponsoring clinical trial NCT01837303?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01837303 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy
RECRUITING
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
PopSci CHW4CervixHealth
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.